Promomed is working on the next generation of a domestic drug for obesity and diabetes in tablets, as reported to TASS by the biopharmaceutical company.
Last week, American Eli Lilly announced the creation of an effective obesity and diabetes drug in tablets. After the news, the shares of its main competitor, the Danish Novo Nordisk, whose product, Ozempic, is available only in ampoules for injection, fell by 10%.
«We are working on various forms of the innovative drugs for the treatment of obesity and diabetes, developing both tablets and long-acting injectables», — Promomed told TASS.
In 2024, the media around the world noted a hype around this drug. Generic versions of Ozempic produced by Russian companies have become very popular in the country. In 2023, Promomed and Geropharm received registration certificates from the the Ministry of Health for their generics of Ozempic (INN semaglutide).
According to The Wall Street Journal, more convenient for patients to take, as well as easier to transport and store.
